WASHINGTON (Reuters) – A cooperation between the United States and three of its closest Indo-Pacific partners to supply up to a billion coronavirus vaccine doses across Asia by the end of 2022 was ‘still on track’, senior administration officials said on Monday, despite a surge of the virus in India, one of the countries involved.
“It’s moving forward expeditiously,” a senior administration official told reporters in a briefing call. In March, a Quad fact sheet said the United States, through its International Development Finance Corp, would work to finance Indian drugmaker Biological E Ltd to produce at least 1 billion COVID-19 vaccine doses by the end of 2022.
(Reporting by Andrea Shalal, Allison Martell and Humeyra Pamuk, Editing by Franklin Paul)
